U.K. sets the bar for COVID-19 master protocols
The world needs to prioritize master protocols for COVID-19 and the U.K. is leading the charge
Master protocol trials have emerged as the fastest path to definitive answers on candidate therapies and vaccines for COVID-19, but in most regions these trials are not getting prioritized over individual clinical studies. The rest of the world can learn from the U.K.’s example of how to coordinate and promote master protocols.
The U.K. government is doing much more than funding adaptive master protocols trials for COVID-19. It has designated a trio of such trials a national priority, and has stepped in to ensure the trials cover different stages of the disease and have the all resources they need to be successful, funneling patients, therapies and trial sites into setting them up for success.
This week, the government added another layer to its centralized strategy, unveiling a master protocol trial dubbed ACCORD aimed at establishing initial clinical validation of therapies before moving them into the three later-stage trials (see “U.K.’s ACCORD Platform Trial”).
This is one of several ways the U.K. is implementing its co-ordinated systems to defeat the pandemic, according to a commentary today in BioCentury by SV Health Investors Managing Partner Kate Bingham (see “How the U.K. Healthcare Sector is Leveraging Its Strengths to Beat COVID-19”).
Master protocol trials